Department of Pediatrics, Endocrine Unit, IRCCS San Raffaele Scientific Institute, Via Olgettina, 60, 20132, Milan, Italy.
Department of Pediatrics, "Pietro Barilla" Children Hospital, University of Parma, via Gramsci, 14, Parma, Italy.
J Clin Immunol. 2020 May;40(4):610-618. doi: 10.1007/s10875-020-00777-8. Epub 2020 Apr 19.
Improved survival in ADA-SCID patients is revealing new aspects of the systemic disorder. Although increasing numbers of reports describe the systemic manifestations of adenosine deaminase deficiency, currently there are no studies in the literature evaluating genital development and pubertal progress in these patients.
We collected retrospective data on urogenital system and pubertal development of 86 ADA-SCID patients followed in the period 2000-2017 at the Great Ormond Street Hospital (UK) and 5 centers in Italy. In particular, we recorded clinical history and visits, and routine blood tests and ultrasound scans were performed as part of patients' follow-up.
We found a higher frequency of congenital and acquired undescended testes compared with healthy children (congenital, 22% in our sample, 0.5-4% described in healthy children; acquired, 16% in our sample, 1-3% in healthy children), mostly requiring orchidopexy. No urogenital abnormalities were noted in females. Spontaneous pubertal development occurred in the majority of female and male patients with a few cases of precocious or delayed puberty; no patient presented high FSH values. Neither ADA-SCID nor treatment performed (PEG-ADA, BMT, or GT) affected pubertal development or gonadic function.
In summary, this report describes a high prevalence of cryptorchidism in a cohort of male ADA-SCID patients which could represent an additional systemic manifestation of ADA-SCID. Considering the impact urogenital and pubertal abnormalities can have on patients' quality of life, we feel it is essential to include urogenital evaluation in ADA-SCID patients to detect any abnormalities, initiate early treatment, and prevent long-term complications.
ADA-SCID 患者生存率的提高揭示了这种全身性疾病的新方面。尽管越来越多的报告描述了腺苷脱氨酶缺乏症的全身表现,但目前文献中尚无研究评估这些患者的生殖器官发育和青春期进展。
我们收集了 2000 年至 2017 年期间在英国大奥蒙德街医院(Great Ormond Street Hospital,GOSH)和意大利 5 个中心接受治疗的 86 例 ADA-SCID 患者的回顾性生殖系统和青春期发育数据。具体而言,我们记录了患者的临床病史和就诊情况,作为患者随访的一部分,还进行了常规血液检查和超声检查。
我们发现,与健康儿童相比,ADA-SCID 患者先天性和获得性隐睾的发生率更高(先天性隐睾在我们的样本中为 22%,而健康儿童中为 0.5-4%;获得性隐睾在我们的样本中为 16%,而健康儿童中为 1-3%),大多数需要进行睾丸固定术。女性未发现生殖系统异常。大多数女性和男性患者的青春期自发发育,但也有少数性早熟或青春期延迟的病例;没有患者出现高 FSH 值。ADA-SCID 或所进行的治疗(PEG-ADA、BMT 或 GT)均未影响青春期发育或性腺功能。
总之,本报告描述了一组 ADA-SCID 男性患者中隐睾的高发生率,这可能是 ADA-SCID 的另一种全身表现。鉴于泌尿生殖系统和青春期异常会对患者的生活质量产生影响,我们认为对 ADA-SCID 患者进行泌尿生殖系统评估以发现任何异常、早期进行治疗并预防长期并发症至关重要。